Key result
Cardiovascular mortality in ovarian cancer drops until 2018 before rising ~4% annually through 2020.
Why the study?
CVD is the leading cause of death among women with ovarian cancer, motivating an investigation of nationwide cardiovascular mortality trends by geography and urbanization.
What are the trends in cardiovascular mortality among women with ovarian cancer in the US from 1999 to 2020?
Observational
Yes
What are the trends in cardiovascular mortality among women with ovarian cancer in the US from 1999 to 2020?
Cardiovascular mortality in ovarian cancer patients declined from 1999 to 2018 but sharply increased from 2018 to 2020, highlighting a need for targeted public health interventions.
Answers are grounded in this paper and cite their sources.
May warrant heightened cardiovascular monitoring in ovarian cancer amid disruptions; leaves open causal confirmation and trend durability.
e17594 Background: Cardiovascular disease (CVD) is the leading cause of death among women with ovarian cancer. This study investigates cardiovascular mortality in women with ovarian cancer across the United States, assessing trends by geography and urbanization. Methods: Mortality data from the CDC WONDER database (1999–2020) were analyzed. Females with ovarian cancer listed on the death certificate and cardiovascular disease as the cause of death were identified using ICD-10 codes. Age-adjusted mortality rates (per 100,000) were calculated and stratified by census region and urbanization. Trends were evaluated using Average Annual Percent Change (AAPC) calculated by the Joinpoint Regression Program V5.4.0. Results: From 1999 to 2018, cardiovascular mortality in ovarian cancer patients declined, with an APC of –2.09%, consistent across regions and urbanization levels. However, from 2018 to 2020, a concerning reversal occurred, with mortality increasing by +3.79% per year. The abrupt rise in mortality is observed in the Midwest region, with an APC of +3.99, and in small and medium metro regions, with APCs of +7.38 and +6.46, respectively. This reversal in cardiovascular mortality in ovarian cancer from 2018 to 2020 is likely due to the COVID-19 pandemic that disrupted screening and treatment. Conclusions: This 21-year analysis demonstrates a long-term decline in cardiovascular mortality among women with ovarian cancer, followed by a sharp reversal from 2018 to 2020. This increase suggests the urgent need for public health interventions to reduce cardiovascular risk among ovarian cancer patients.
No takes yet. Share an insight, caveat, or question.
Sehbai et al. (2026) conducted an observational in Ovarian cancer and cardiovascular disease. Women with ovarian cancer experienced a decline in cardiovascular mortality from 1999 to 2018 (APC -2.09%), followed by a sharp increase from 2018 to 2020 (APC +3.79%).
Synapse has enriched 10 related papers. Consider them for comparative context: